16th August, 2024
PoC breath diagnostics detecting volatile organic compound biomarkers
image credit- shutterstock
Detect-ION, the pioneering Deep-Tech startup headquartered in Tampa, Florida, has partnered with Moffitt Cancer Center for lung cancer early detection through next-generation breath diagnostics.
The pilot project, sponsored by Detect-ION, introduces rapid, non-invasive, ultra-low-cost, point-of-care (PoC) breath diagnostics, offering a transformative approach to early lung cancer diagnosis. The pilot study will leverage Detect-ION's chip-scale mass spectrometry platform, named "CLARION," to demonstrate key VOC biomarkers distinguishing lung cancer-positive patients from healthy controls.
Ashish Chaudhary, PhD, CEO of Detect-ION and principal investigator of the pilot study shared, "By utilizing trace-level chemical signatures to identify volatile organic compound (VOC) biomarkers at parts per trillion concentrations in exhaled breath, Detect-ION is developing a low-cost, patient-friendly, in-home test for diagnosing lung cancer. While it's a complex sensing technology, think of it as quick and easy as blowing up a small balloon."
Medtech Special
Artificial Intelligence Breakthroughs
Robots In Medtech
© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer